XBiotech Inc. — Q2 2021 Form 10-Q
Reporting period: Quarter and six months ended June 30, 2021. XBiotech is a pre-commercial biopharmaceutical company developing naturally derived “True Human” monoclonal antibodies, including candidates targeting IL-1α. The financial statements are unaudited; amounts below are in U.S. dollars unless stated otherwise.
Financial performance and position
| Metric | Q2 2021 | Q2 2020 | Six months 2021 | Six months 2020 |
|---|---|---|---|---|
| Revenue | $4.5 million | $15.5 million | $9.4 million | $28.2 million |
| Gross margin (reported dollars) | $3.2 million | $2.3 million | $5.7 million | $5.3 million |
| Operating expenses | $13.8 million | $8.8 million | $19.9 million | $14.0 million |
| Operating loss | $10.6 million | $6.5 million | $14.2 million | $8.7 million |
| Net loss | $5.1 million | $6.8 million | $7.7 million | $6.9 million |
| Basic and diluted loss per share | $0.17 | $0.24 | $0.26 | $0.21 |
- Revenue primarily reflects Janssen-related clinical manufacturing and trial services. Manufacturing revenue was $4.5 million in Q2 and $9.0 million for the six-month period. Clinical trial service revenue was $25,000 and $375,000, respectively.
- Research and development expense increased to $9.3 million for Q2 and $13.9 million for the first half, from $2.6 million and $3.7 million a year earlier. General and administrative expense declined to $4.5 million and $6.0 million, respectively, from $6.2 million and $10.3 million.
- Cash and cash equivalents were $315.3 million at June 30, 2021, versus $237.4 million at December 31, 2020. Current assets were $324.9 million and current liabilities $3.9 million. Total liabilities were $5.4 million; the balance sheet reports no borrowings.
- Six-month operating cash flow was $74.6 million, investing cash outflow $2.3 million, and financing cash inflow $5.0 million. The operating cash inflow was primarily driven by receipt of a $75 million Janssen escrow amount. Capital spending included building expansion and warehouse construction.
Changes, outlook, and risks
- Revenue fell sharply year over year as Janssen-related clinical trial activity declined following completion of trials. The company says the manufacturing agreement pays $4.5 million per quarter through 2021 and expires December 31, 2021; it expects no further revenue under that agreement after expiration.
- Management attributed higher R&D costs partly to expense reclassification, increased personnel and supplies, and the start of a new Phase I trial for a new indication. It said a $7.0 million CEO bonus paid in June 2021 was allocated 60% to R&D and 40% to G&A.
- The company expects increasing operating losses as it advances candidates through development and says it must generate significant revenue to reach or sustain profitability. Management stated that cash should fund operations for the foreseeable future and support major development milestones.
- On July 6, 2021, the board declared an extraordinary cash dividend; shareholders of record received $2.47 per share on July 23, 2021. This post-period event is not reflected in June 30 cash.
- Reported six-month income tax benefit was $5.0 million; the filing cites loss carrybacks in Canada and discrete tax items. The company maintains valuation allowances against certain deferred tax assets and reported $2.4 million of unrecognized tax benefits at year-end 2020, increased by $271,000 during the first half of 2021.
- Management reported no material change to the 2020 Form 10-K risk factors and no material market-risk exposure or change in internal control over financial reporting. Key risks include clinical and regulatory uncertainty, ability to fund development, competition, intellectual property protection, and potential pandemic-related disruption.
Investor facts to verify
- Reconcile the $75 million escrow receipt included in operating cash flow with underlying Janssen transaction terms and confirm remaining cash after the July dividend.
- Review the CEO bonus amount, allocation between R&D and G&A, and its effect on reported expenses.
- Confirm the timing and financial impact of the December 2021 expiration of manufacturing revenue, and distinguish recurring revenue from pass-through clinical-service amounts.
- Assess the new Phase I program and other pipeline milestones against management’s cash runway expectations and anticipated spending.
- Review tax-benefit assumptions, valuation allowances, and the resolution or potential change in uncertain tax positions.